Citigroup Inc Uro Gen Pharma Ltd. Transaction History

Citigroup Inc

$150 Billion
Q1 2024

A detailed history of Citigroup Inc transactions in Uro Gen Pharma Ltd. stock. As of the latest transaction made, Citigroup Inc holds 4,838 shares of URGN stock, worth $76,827. This represents 0.0% of its overall portfolio holdings.

Number of Shares

4,838

Previous 18,684 74.11%

Holding current value

$76,827

Previous $280,000 74.29%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	SELL	$13.81 - $19.33 $191,213 - $267,643	-13,846 Reduced 74.11%	4,838 $72,000
Q4 2023 Feb 09, 2024	BUY	$10.87 - $15.93 $198,681 - $291,168	18,278 Added 4501.97%	18,684 $280,000
Q3 2023 Nov 09, 2023	SELL	$8.84 - $22.64 $51,431 - $131,719	-5,818 Reduced 93.48%	406 $5,000
Q2 2023 Aug 10, 2023	SELL	$8.75 - $14.29 $426,002 - $695,722	-48,686 Reduced 88.67%	6,224 $64,000
Q1 2023 May 11, 2023	BUY	$7.99 - $11.02 $2,357 - $3,250	295 Added 0.54%	54,910 $507,000

Q4 2022 Feb 09, 2023	BUY	$7.55 - $11.9 $409,844 - $645,979	54,284 Added 16400.0%	54,615 $484,000
Q3 2022 Nov 10, 2022	SELL	$7.21 - $9.41 $2,956 - $3,858	-410 Reduced 55.33%	331 $3,000
Q2 2022 Aug 10, 2022	SELL	$5.12 - $8.74 $2,488 - $4,247	-486 Reduced 39.61%	741 $6,000
Q1 2022 May 12, 2022	SELL	$5.92 - $9.73 $25,959 - $42,666	-4,385 Reduced 78.14%	1,227 $11,000
Q4 2021 Feb 10, 2022	BUY	$9.03 - $19.13 $19,586 - $41,492	2,169 Added 63.0%	5,612 $53,000
Q3 2021 Nov 10, 2021	BUY	$14.31 - $18.39 $49,269 - $63,316	3,443 New	3,443 $58,000

Others Institutions Holding URGN

# of Institutions

113

Shares Held

24M

Call Options Held

46.9K

Put Options Held

44.3K

View Full List

About UroGen Pharma Ltd.

Ticker URGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 22,740,500
Market Cap $361M
Description
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead...

More about URGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.

Account